These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

850 related articles for article (PubMed ID: 30126458)

  • 1. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No evidence for clinical efficacy of adjunctive celecoxib with vortioxetine in the treatment of depression: A 6-week double-blind placebo controlled randomized trial.
    Baune BT; Sampson E; Louise J; Hori H; Schubert KO; Clark SR; Mills NT; Fourrier C
    Eur Neuropsychopharmacol; 2021 Dec; 53():34-46. PubMed ID: 34375789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation-stratified augmentation of vortioxetine with celecoxib: Results from a double-blind, randomized, placebo-controlled trial in major depressive disorder.
    Kavakbasi E; Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert KO; Clark SR; Fourrier C; Baune BT
    J Neurochem; 2024 Sep; 168(9):1817-1825. PubMed ID: 37635396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term characterisation of the relationship between change in depression severity and change in inflammatory markers following inflammation-stratified treatment with vortioxetine augmented with celecoxib or placebo.
    Sampson E; Mills NT; Hori H; Cearns M; Schwarte K; Hohoff C; Oliver Schubert K; Fourrier C; Baune BT
    Brain Behav Immun; 2025 Jan; 123():43-56. PubMed ID: 39243988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emotional Blunting in Depression in the PREDDICT Clinical Trial: Inflammation-Stratified Augmentation of Vortioxetine With Celecoxib.
    Sampson E; Kavakbasi E; Mills NT; Hori H; Schubert KO; Fourrier C; Baune BT
    Int J Neuropsychopharmacol; 2024 Mar; 27(3):. PubMed ID: 38441216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA; Loft H; Olsen CK
    J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
    Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial.
    Mills NT; Sampson E; Fourrier C; Baune BT
    Int J Neuropsychopharmacol; 2021 Apr; 24(4):314-321. PubMed ID: 33269395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
    J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
    [No Abstract]   [Full Text] [Related]  

  • 10. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of inflammation-based stratification for add-on celecoxib or minocycline in major depressive disorder: Protocol of the INSTA-MD double-blind placebo-controlled randomised clinical trial.
    Wessa C; Janssens J; Coppens V; El Abdellati K; Vergaelen E; van den Ameele S; Baeken C; Zeeuws D; Milaneschi Y; Lamers F; Penninx B; Claes S; Morrens M; De Picker L
    Brain Behav Immun Health; 2024 Nov; 41():100871. PubMed ID: 39350954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
    Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline Cognition Is Not Associated With Depression Outcomes in Vortioxetine for Major Depressive Disorder: Findings From Placebo-Controlled Trials.
    Jordan JT; Shen L; Cooper NJ; Goncalves SV; Trivedi MH; Schatzberg AF; Wu W; Savitz AJ; Etkin A
    J Clin Psychiatry; 2024 Sep; 85(4):. PubMed ID: 39240698
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.
    Mahableshwarkar AR; Jacobsen PL; Chen Y; Serenko M; Trivedi MH
    Psychopharmacology (Berl); 2015 Jun; 232(12):2061-70. PubMed ID: 25575488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
    Zhou J; Wang W; Yang J; Zhu X; Feng L; Xiao L; Wang G
    Trials; 2019 Jan; 20(1):33. PubMed ID: 30626409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): study protocol for a randomised control trial.
    Davey CG; Chanen AM; Cotton SM; Hetrick SE; Kerr MJ; Berk M; Dean OM; Yuen K; Phelan M; Ratheesh A; Schäfer MR; Amminger GP; Parker AG; Piskulic D; Harrigan S; Mackinnon AJ; Harrison BJ; McGorry PD
    Trials; 2014 Nov; 15():425. PubMed ID: 25370185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction.
    Jacobsen PL; Mahableshwarkar AR; Chen Y; Chrones L; Clayton AH
    J Sex Med; 2015 Oct; 12(10):2036-48. PubMed ID: 26331383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder.
    Nadi Sakhvidi M; Salami Z; Mosadegh M; Bidaki R; Fallahzadeh H; Salehabadi R; Arjmandi M
    Int J Psychiatry Med; 2024 Sep; 59(5):511-520. PubMed ID: 38116669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial.
    Akhondzadeh S; Jafari S; Raisi F; Nasehi AA; Ghoreishi A; Salehi B; Mohebbi-Rasa S; Raznahan M; Kamalipour A
    Depress Anxiety; 2009; 26(7):607-11. PubMed ID: 19496103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.